Photo: Angiography suite. Sandro Porfirio / Unsplash
1. Boston Scientific's Obsidio embolic occluded all target vessels in 125-patient U.S. registry
Final OCCLUDE registry results for the shear-thinning conformable embolic are published in JVIR.
The prospective, post-approval OCCLUDE registry enrolled 125 patients aged 18 to 92 at 19 U.S. hospitals and reported immediate occlusion in 100% of 161 target lesions across 19 target vessels, most often renal (25.5%) and musculoskeletal (19.3%) [1][2]. No target vessel rebleeding or reintervention occurred through 30 days, freedom from adverse events was 97.4%, and adjunctive coils, beads or gelatin sponge were used in 23.6% of procedures [1][2]. The paper, by Ketan Y. Shah, MD, and colleagues, appears in JVIR [1].
2. FDA approves Infilbray, first drug for neurological symptoms of type 3 Gaucher disease
An oral glucosylceramide synthase inhibitor that crosses the blood-brain barrier.
The FDA on Nov. 18 approved Sanofi's Infilbray (venglustat) tablets for the neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg [3]. In a 43-patient randomized, double-blind trial, patients 12 and older taking Infilbray once daily improved at week 52 on a combined ataxia and cognition measure compared with those on IV enzyme replacement therapy [3]. Serious psychiatric risks, including suicidal ideation, have been reported [3].
3. FDA approves Regeneron's Livsayis, first siRNA therapy for generalized myasthenia gravis
Four subcutaneous doses a year, with a boxed warning for meningococcal infection.
Livsayis (cemdisiran), approved Nov. 18 for adults with anti-AChR antibody-positive generalized myasthenia gravis, degrades the mRNA for complement C5 and is injected once every three months [4][5]. In the Phase 3 NIMBLE trial, MG-ADL scores improved 4.5 points at week 24 versus 2.2 on placebo, and 76.6% of treated patients gained at least 3 points versus 44.1% on placebo [4][5]. The label carries a boxed warning for serious meningococcal infections, and the drug is available only through a REMS program [4].
4. Michigan pharmacy owner sentenced to 82 months for $5.6M fraud and oxycodone distribution
Forged prescriptions billed to Medicare, Medicaid and Blue Cross, plus cash sales to drug traffickers.
The Justice Department said Nov. 18 that Ali Naserdean, 32, of Dearborn Heights, a pharmacy technician who owned one of three metro-Detroit pharmacies where he worked, was sentenced to 82 months in prison and three years of supervised release [6]. From 2019 through 2022, he and pharmacist Isaiah Okoh billed more than $5.6 million for prescriptions never ordered by a doctor or dispensed, hiding the scheme with forged prescriptions, while Naserdean separately distributed oxycodone to drug traffickers for cash [6]. He pleaded guilty in April 2026 and owes more than $3.6 million in restitution; Okoh was sentenced in December 2025 to more than six years [6].
Digest references
Endovascular Today, "OCCLUDE Registry Data Published for Boston Scientific's Obsidio Conformable Embolic," Nov. 17, 2026. evtoday.com
Boston Scientific, "Obsidio OCCLUDE Registry" (data summary). bostonscientific.com
U.S. Food and Drug Administration, "FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease," Nov. 18, 2026. fda.gov
Regeneron Pharmaceuticals, "Livsayis (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis," Nov. 18, 2026. investor.regeneron.com
Drugs.com, "Livsayis (cemdisiran) FDA Approval History," Nov. 18, 2026. drugs.com
U.S. Department of Justice, "Pharmacy Owner Sentenced to 82 Months in Prison for $5.6M Health Care Fraud Scheme and Illegal Distribution of Oxycodone," Nov. 18, 2026. justice.gov